AGPS and neoplasm: Although neoplasms were identified in the induction and maintenance studies, these were considered unrelated to ontamalimab, which was consistent with previous findings.21,24 A similar proportion of patients who received ontamalimab or placebo developed ADAs, and few patients developed NAbs, which suggests that this fully human monoclonal antibody was not meaningfully immunogenic in these studies.21,24